Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Bajorin

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2001
Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancerD F Bajorin
Oncology (Williston Park, N.Y.)|February 19, 2000
Paclitaxel in the treatment of advanced urothelial cancerD F Bajorin
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tractD F Bajorin
Seminars in Oncology|October 1, 1994
Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparisonG J Bosl, D F Bajorin
The Journal of Urology|March 1, 1995
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) worldB J Roth, D F Bajorin
Current Opinion in Urology|October 14, 2006
New chemotherapy regimens for metastatic bladder cancerP M Dodd, D F Bajorin
Seminars in Oncology|April 30, 1998
Therapy for good risk germ cell tumorsJ A McCaffrey, D F Bajorin
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Continued refinement in the treatment of germ cell tumour patientsD F Bajorin, G J Bosl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Bleomycin in germ cell tumor therapy: not all regimens are created equalD F Bajorin, G J Bosl
Seminars in Urologic Oncology|March 15, 2001
Chemotherapy agents in transitional cell carcinoma: the old and the newF C Maluf, D F Bajorin
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2001
Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancerD F Bajorin
Oncology (Williston Park, N.Y.)|February 19, 2000
Paclitaxel in the treatment of advanced urothelial cancerD F Bajorin
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tractD F Bajorin
Seminars in Oncology|October 1, 1994
Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparisonG J Bosl, D F Bajorin
The Journal of Urology|March 1, 1995
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) worldB J Roth, D F Bajorin
Current Opinion in Urology|October 14, 2006
New chemotherapy regimens for metastatic bladder cancerP M Dodd, D F Bajorin
Seminars in Oncology|April 30, 1998
Therapy for good risk germ cell tumorsJ A McCaffrey, D F Bajorin
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Continued refinement in the treatment of germ cell tumour patientsD F Bajorin, G J Bosl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Bleomycin in germ cell tumor therapy: not all regimens are created equalD F Bajorin, G J Bosl
Seminars in Urologic Oncology|March 15, 2001
Chemotherapy agents in transitional cell carcinoma: the old and the newF C Maluf, D F Bajorin
Pageof 10